Eli Lilly (LLY) benefits from "lots of untapped volume to capture" in the obesity drug market ever after Zepbound's exclusion from CVS Health's (CVS) preferred list, Deutsche Bank said Friday in a note.
"Commercialization of the chronic obesity opportunity is still in early innings" after Lilly's Zepbound launched in December 2023 and Novo Nordisk's (NVO) Wegovy debuted in June 2021, the report said.
Customers are likely opting for Zepbound after trials demonstrating a 20% weight loss advantage versus Wegovy at 14% after 72 weeks, Deutsche Bank said.
Zepbound's cash-pay vial at $349 to $499 a month is "virtually on par with Wegovy's new to brand scripts," the report said.
Deutsche Bank reiterated its buy rating on Lilly stock with a 12-month target price of $1,010.
Lilly shares rose 2.9% in recent Friday trading, and Novo Nordisk jumped 5.3%.
Price: 816.97, Change: +22.87, Percent Change: +2.88
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。